NRG1 and pancreatic neoplasm: Interestingly, recent results from the Phase 2 TAPUR basket study (NCT02693535) showed that afatinib exhibited clinical activity in three patients with NRG1 fusion-positive tumors, including lung, colorectal, and pancreatic tumor types (Fig. 1c).4 However, larger cohort studies are needed to confirm its efficacy in NRG1 fusion-positive tumors.